
Loretta Swit, 'Hot Lips' Houlihan on 'M*A*S*H,' dies at 87
Swit, a mainstay of one of the most successful and acclaimed series in U.S. television history, died at her home in New York City from what was suspected to be natural causes, her publicist, Harlan Boll, said.
Swit earned two best supporting actress Emmys and 10 nominations for her role as "Hot Lips," the lusty, tough but vulnerable, patriotic Army career nurse in the series that ran from 1972-1983.
As the only regular female character in the groundbreaking show set in the fictional 4077th Mobile Army Surgical Hospital during the Korean War of the 1950s, "Hot Lips" endured the insults, pranks and practical jokes of the fun-loving male surgeons. The show's cast also included Alan Alda, Wayne Rogers, McLean Stevenson, Larry Linville, Mike Farrell, Harry Morgan, Gary Burghoff, David Ogden Stiers and Jamie Farr.
Swit defined her role by playing a strong, determined, independent woman, who had input into the development and storyline of her character, including her split from her married lover Major Frank Burns, hilariously played by Linville, and her own wedding and divorce.
She appeared in nearly all of the more than 250 episodes and the series finale, which was the most watched episode of any TV series in history when the show ended in 1983.
The TV series was based on the real-life experiences of an Army surgeon, who penned the 1968 book "MASH: A Novel About Three Army Doctors," and on director Robert Altman's 1970 black comedy film of the same name.
"While we were shooting, even from the very beginning, we were aware of how very special it was," Swit said about the series in a 2017 interview with Fox News. "The symbiosis, the camaraderie, the love and respect we had for each other."
Loretta Swit was born on November 4, 1937, in Passaic, New Jersey. After finishing school, and against her strict parents' objections, she began training as an actress at the American Academy of Dramatic Arts in New York. She worked as a stenographer while auditioning for roles.
"The first thought I ever had in my head was being an actress. I can't remember ever not wanting to perform,' she told the Star magazine in a 2010 interview.
The tall, blonde stage and TV star was a strict vegetarian and animal lover. She started her career in theater and appeared in guest roles in TV dramas such as "Gunsmoke," "Mannix," "Bonanza" and the original "Hawaii Five-O," before landing her signature role.
Swit also originated the character of Detective Christine Cagney in the pilot for "Cagney & Lacey" but could not take on the role in the TV series because of her contract with "M*A*S*H".
The actress made her Broadway debut in "Same Time, Next Year" in 1975. She performed in the musical "Mame" on tour and starred in the one-woman play "Shirley Valentine" more than 1,000 times over three decades.
"Acting is not hiding to me, it's revealing. We give you license to feel," she said in an interview with the Star magazine in 2010. "That's the most important thing in the world, because when you stop feeling, that's when you're dead.'
After "M*A*S*H" Swit appeared in TV movies, on game shows and on the stage and in films but she never found the same level of fame. She also devoted herself to animal rights and was a former spokesperson for the Humane Society of the United States.
She married actor Dennis Holahan, who played a Swedish diplomat in an episode of "M*A*S*H," in 1983. The couple divorced in 1995 and had no children.
Although "M*A*S*H" ended decades ago, Swit found new generations of fans through syndication of the series.
"The show has never been off the air! A lot of people don't realize that," Swit told the Huffington Post in 2018. "I've seen it in Thailand, in Egypt ... It's a phenomenon."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Daily Mail
3 minutes ago
- Daily Mail
Billionaire bowling heir Peter Goodwin to face wife in $50M divorce showdown after dumping her for kids' nanny
The Virginia billionaire love cheat and the wife he dumped on Christmas Day for their ex-nanny will face each other at a two-day divorce trial, Daily Mail can exclusively reveal. Bowling heir Peter Goodwin and estranged spouse Cara, a leading psychologist and mom of their four young children, are set to do battle in a Charlottesville court, according to legal papers.


The Guardian
3 minutes ago
- The Guardian
Sharon Stone says she's not involved in Basic Instinct reboot:‘I don't know why you'd do it'
The actor Sharon Stone has expressed scepticism about the Basic Instinct reboot currently being scripted by the original film's writer Joe Eszterhas. Speaking on US TV's Today programme, Stone made reference to the unsuccessful 2006 sequel, in which she reprised her role of murderous novelist Catherine Tramell. That film earned dreadful reviews, poor audience feedback and just $38m (£28m) at the global box office, compared to the original's $353m (£261m). 'If it goes the way the one that I was in went, I would just say, I don't know why you'd do it,' said Stone. 'I mean, go ahead, but good fucking luck.' She continued by questioning the logistics of her character's return. 'I'm at that stage where I already retired once, and I already died a couple of times,' Stone said. 'I'm like, 'What are you gonna do? Kill me again? Go ahead.'' Stone, who is now promoting Nobody 2, went on to say she 'pretty much owned the 90s as an actress' before explaining that a stroke that led to a brain haemorrhage in 2001 stopped her working. She then took time out to raise a family before returning to acting. 'I want to leave it on the screen,' she said, 'because it lasts for ever, and I won't. And I'm sure of that.' Last month is was reported that Eszterhas, 80, has signed a deal with Amazon MGM: the streamer guarantees a $2m (£1.5m) fee for his new Basic Instinct script, which will be upped to $4m (£3m) should the film be made, making it the most lucrative spec sale of the year. 'To those who question what an 80-year-old man is doing writing a sexy, erotic thriller: the rumours of my cinematic impotence are exaggerated and ageist,' Esztherhas said, in a statement to the Wrap. 'I call my writing partner the TWISTED LITTLE MAN and he lives somewhere deep inside me. He was born 29 and he will die 29 and he tells me he is 'sky high up' to write this piece and provide viewers with a wild and orgasmic ride. That makes me very happy.'


Reuters
3 minutes ago
- Reuters
Viking's oral pill reduces up to 12.2% weight but shares slump on higher patient exits
Aug 19 (Reuters) - Viking Therapeutics (VKTX.O), opens new tab said on Tuesday its experimental weight-loss pill helped people with obesity lose up to 12.2% of their body weight over 13 weeks in a keenly watched study. Yet, shares of the company slumped nearly 35% in premarket trading after data showed that more patients who received Viking's drug stopped taking the treatment, compared to those who received placebo in the mid-stage study. Oral drugs are expected to take a significant share of the projected $150 billion weight-loss market, driven by their ease of use compared with injections such as Novo Nordisk's ( opens new tab Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound. Viking's experimental oral pill is in a tight race with rival treatments being developed by the deeper-pocketed Novo and Lilly. Earlier this month, Eli Lilly said its experimental daily pill, orforglipron, showed a 12.4% weight loss in patients in a late-stage study over 72 weeks. In a separate trial, Novo's oral semaglutide has shown a weight loss of 15% over 68 weeks. Both the oral drugs are expected to be launched next year. Ahead of Viking's data, analysts expected weight loss in the range of 10% to 15% on average for the pill, known as VK2735. It had shown an 8.2% average weight-loss in a small early-stage trial. About 20% of those who received the drug discontinued due to an adverse effect, compared to 13% on placebo in the 280-patient study. The most common reasons for treatment discontinuation were gastrointestinal side effects, the company said. Like Lilly's Zepbound, Viking's drug also targets hormones known as GLP-1 and GIP that play a critical role in regulating the body's metabolism. Viking is testing both the oral and under-the-skin injection forms of the drug in overweight patients who have who at least one weight-related comorbidity.